Business · 1 sources covering this

Street stays bullish on Sun Pharma despite mixed Q2, earnings downgrades

Analysts remain positive on Sun Pharma despite slower US and speciality growth in Q2FY27, supported by strong domestic sales, though near-term earnings estimates have been cut.

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

Business StandardCenter·2h ago
Street stays bullish on Sun Pharma despite mixed Q2, earnings downgrades
Analysts remain positive on Sun Pharma despite slower US and speciality growth in Q2FY27, supported by strong domestic sales, though near-term earnings estimates have been cut.
Read at Business Standard →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/5522b08900f0fb04b3d3b6624cd911e17e787389"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Street stays bullish on Sun Pharma despite mixed Q2, earnings downgrades"></iframe>

Street stays bullish on Sun Pharma despite mixed Q2, earnings downgrades

How 1 sources are covering this

Street stays bullish on Sun Pharma despite mixed Q2, earnings downgrades

More from Business

Capex push to continue, but fiscal prudence non-negotiable: FM

Cyclone Murasu likely to bring heavy rainfall across southern states

GRAP 2 in Delhi: What's allowed; what is not? Which cars, vehicles are banned? Check list before going to office

What makes Pune Metro's Pink Line so special?

Reader

Trust & legal

Across the network